A biopharmaceutical company announced it has dosed the first patient in a clinical trial of a long-acting oral treatment for schizophrenia, schizoaffective disorder and bipolar I disorder, according to a company press release.
Increase in Research and Development activities for advancements in anti-psychotic drugs, product launches, and approvals has increased the Schizophrenia market. An increase in the development